{"drugs":["Geref","Geref Diagnostic","Sermorelin Acetate"],"mono":{"0":{"id":"542000-s-0","title":"Generic Names","mono":"Sermorelin Acetate"},"1":{"id":"542000-s-1","title":"Dosing and Indications","sub":{"1":{"id":"542000-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Effective October 2008, sermorelin acetate (Geref(R) Diagnostic) will no longer be available.<\/li><li><b>Growth hormone deficiency:<\/b> 30 mcg\/kg SC daily at bedtime; discontinue when epiphyses are fused<\/li><li><b>Growth hormone deficiency; Diagnosis:<\/b> after overnight fast, 1 mcg\/kg IV over 30 sec<\/li><\/ul>"},"3":{"id":"542000-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Effective October 2008, sermorelin acetate (Geref(R) Diagnostic) will no longer be available [1].<\/li><li>Growth hormone deficiency<\/li><li>Growth hormone deficiency; Diagnosis<\/li><\/ul>"}}},"3":{"id":"542000-s-3","title":"Contraindications\/Warnings","sub":[{"id":"542000-s-3-9","title":"Contraindications","mono":"hypersensitivity to sermorelin products<br\/>"},{"id":"542000-s-3-10","title":"Precautions","mono":"<ul><li>geriatric use (patients 65 years of age or olders)<\/li><li>growth hormone deficiency secondary to an intracranial lesion<\/li><\/ul>"},{"id":"542000-s-3-11","title":"Pregnancy Category","mono":"Sermorelin: C (FDA)<br\/>"},{"id":"542000-s-3-12","title":"Breast Feeding","mono":"Sermorelin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"542000-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Flushing, Sermorelin diagnostic, Injection site reaction, Local pain, swelling, redness<\/li><li><b>Immunologic:<\/b>Antibody development<\/li><\/ul>"},"6":{"id":"542000-s-6","title":"Drug Name Info","sub":{"0":{"id":"542000-s-6-17","title":"US Trade Names","mono":"<ul><li>Geref<\/li><li>Geref Diagnostic<\/li><\/ul>"},"2":{"id":"542000-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Growth Hormone Releasing Hormone Analog<\/li><\/ul>"},"3":{"id":"542000-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"542000-s-7","title":"Mechanism Of Action","mono":"Sermorelin acetate, also called growth releasing hormone (1-29) and growth hormone releasing hormone (1-29), directly stimulates the pituitary gland to release growth hormone (GH), thus increasing plasma GH concentrations.<br\/>"},"9":{"id":"542000-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>diagnostic; reconstitute with accompanying sterile diluent<\/li><li>diagnostic; follow with a 3 mL NS flush<\/li><li>diagnostic; give in morning following an overnight fast<\/li><\/ul>"},"10":{"id":"542000-s-10","title":"Monitoring","mono":"growth hormone deficiency-diagnosis: blood sampling 15 min and immediately prior to injection and at 15-min intervals for up to 1 hr following injection <br\/>"},"13":{"id":"542000-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause flushing.<\/li><li>Patient should fast overnight prior to administration of drug.<\/li><\/ul>"}}}